Foxo1-Rictor axis mediates adaptive increase in Akt activity and cell survival during BCR inhibitor therapy in chronic lymphocytic leukemia.
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F23%3A00132964" target="_blank" >RIV/00216224:14740/23:00132964 - isvavai.cz</a>
Result on the web
<a href="https://cancermeeting.cz/czech-annual-cancer-research-meeting-2023/" target="_blank" >https://cancermeeting.cz/czech-annual-cancer-research-meeting-2023/</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Foxo1-Rictor axis mediates adaptive increase in Akt activity and cell survival during BCR inhibitor therapy in chronic lymphocytic leukemia.
Original language description
Genetic resistance mechanisms to BCR inhibitors in CLL have been extensively described, but it remains unclear whether non-genetic adaptation might exist in CLL cells allowing for lasting lymphocytosis or resistance. We focused on the possible role of the Akt pathway in adapting to BCR inhibitors since, in mouse models, PI3K-Akt activation is the only known factor that rescues the apoptosis induced by BCR deletion in mature B cells.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů